

ORTHOFIX INTERNATIONAL N V  
Form 8-K  
January 09, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2018

Orthofix International N.V.

(Exact name of Registrant as specified in its charter)

Curaçao (State or other jurisdiction of incorporation)	0-19961 (Commission File Number)	98-1340767 (IRS Employer Identification No.)
--	--	--

7 Abraham de Veerstraat Curaçao (Address of principal executive offices)	N/A (Zip Code)
---	-------------------

Registrant's telephone number, including area code: 599-9-4658525

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On January 9, 2018, Orthofix International N.V. (the “Company”) issued a press release announcing, among other things, its preliminary unaudited net sales for the fiscal quarter and year ended December 31, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 and attached hereto.

Item 7.01. Regulation FD Disclosure.

As previously announced, the Company’s President and Chief Executive Officer, Brad Mason, will provide an investor presentation at 8:30 a.m. Pacific Time on Thursday, January 11, 2018, at the J.P. Morgan Healthcare Conference in San Francisco. A live audio webcast will be available on the Company’s website at [ir.orthofix.com/events.cfm](http://ir.orthofix.com/events.cfm).

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

99.1 Press Release, dated January 9, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Orthofix International  
N.V.

By: /s/ Kimberley Elting  
Kimberley Elting

Chief Legal Officer

Date: January 9, 2018